View : 23 Download: 3

Efficacy and safety of modified pranlukast (Prakanon®) compared with pranlukast (Onon®): A randomized, open-label, crossover study

Title
Efficacy and safety of modified pranlukast (Prakanon®) compared with pranlukast (Onon®): A randomized, open-label, crossover study
Authors
Kim S.W.Kim H.Ryu Y.J.Lee J.H.Shim S.S.Kim Y.K.Chang J.H.
Ewha Authors
장중현심성신
SCOPUS Author ID
장중현scopus; 심성신scopus
Issue Date
2016
Journal Title
Open Respiratory Medicine Journal
ISSN
1874-3064JCR Link
Citation
vol. 10, pp. 36 - 45
Keywords
AsthmaAsthma control testLeukotriene receptor antagonistPranlukast
Publisher
Bentham Science Publishers B.V.
Indexed
SCOPUS scopus
Abstract
Introduction: Pranlukast is a leukotriene receptor antagonist (LTRA) that is used as an additional controller of mild to moderate asthma. This study compared the efficacy and side effects of two bioequivalent preparations of pranlukast: original pranlukast (Onon®; Ono Pharmaceutical, Japan) and a modified formulation of pranlukast (Prakanon®; Yuhan Co, Korea) in patients with mild to moderate asthma. Methods: Of the 34 subjects screened, 30 patients who were using standard medication to control asthma and scored less than 20 points on the Asthma Control Test™ (ACT) were assigned randomly to one of the two groups in a prospective, open label, crossover study: group 1 received Prakanon® (150 mg/day) and group 2 received Onon® (450 mg/day) for 8 weeks each; after a 1-week rest period, the groups were switched to the alternative medication for further 8 weeks and monitored for 2 more weeks without study medication. Evaluation parameters included the ACT, quality of life questionnaire adult Korean asthmatics (QLQAKA), pulmonary function tests, peripheral blood tests, vital signs, and adverse events. Results: Thirty patients were enrolled and 21 completed the trial: 10 in group 1 and 11 in group 2. The baseline data of the two groups did not differ. No statistical significant differences were observed in efficacy and lung function at each time and in changes from baseline value between the two kinds of pranlukast. The final asthma control rate was 81% with Prakanon® and 76% with Onon®. There were no differences in vital signs and laboratory data at each time and in changes from baseline value between the two drugs. There were no differences in adverse events between the two drugs. The most common side effect was abdominal pain. Drug compliance was high, without differences between the two drugs. Conclusion: These findings suggest that Prakanon® which is an improved formulation of pranlukast at a lower dose than the original formulation, Onon®, has a similar efficacy and side effect profile in the control of persistent asthma. © Kim et al.
DOI
10.2174/1874306401610010036
Appears in Collections:
의학전문대학원 > 의학과 > Journal papers
Files in This Item:
Efficacy and safety of modified pranlukast (Prakanon®) compared with pranlukast (Onon®).pdf(804.91 kB)Download
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE